Alpha-v Integrins as Therapeutic Targets in Oncology

REFERENCES

• Mizejewski G. J. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999; 222: 124–138
   PubMed Web of Science ®Google Scholar
• van der Flier A., Sonnenberg A. Function and interactions of integrins. Cell Tissue Res. 2001; 305: 285–298
   PubMed Web of Science ®Google Scholar
• Stupack D. G., Cheresh D. A. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci. 2002; 115: 3729–3738, (Pt 19)
   PubMed Web of Science ®Google Scholar
• Merviel P., Challier J. C., Carbillon L., Foidart J. M., Uzan S. The role of integrins in human embryo implantation. Fetal Diagn Ther. 2001; 16(6)364–371
   PubMed Web of Science ®Google Scholar
• Schuppan D., Ocker M. Integrin-mediated control of cell growth. Hepatology. 2003; 38(2)289–291
   PubMed Web of Science ®Google Scholar
• Curley G. P., Blum H., Humphries M. J. Integrin antagonists. Cell Mol. Life Sci. 1999; 56(5–6)427–441
   PubMed Web of Science ®Google Scholar
• Hood J. D., Cheresh D. A. Role of integrins in cell invasion and migration. Nat. Rev Cancer. 2002; 2(2)91–100
   PubMed Web of Science ®Google Scholar
• Plow E. F., Haas T. A., Zhang L., Loftus J., Smith J. W. Ligand binding to integrins. J Biol Chem 2000; 275(29)21785–21788
   PubMed Web of Science ®Google Scholar
• Kerr J. S., Slee A. M., Mousa S. A. The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig. Drugs 2002; 11(12)1765–1774
   PubMed Web of Science ®Google Scholar
• Guo W., Giancotti F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004; 5(10)816–826
   PubMed Web of Science ®Google Scholar
• Gutheil J. C., Campbell T. N., Pierce P. R., Watkins J. D., Huse W. D., Bodkin D. J., Cheresh D. A. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000; 6(8)3056–3061
   PubMed Web of Science ®Google Scholar
• Patel S. R., Jenkins J., Papadopolous N., Burgess M. A., Plager C., Gutterman J., Benjamin R. S. Pilot study of vitaxin–an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer. 2001; 92(5)1347–1348
   PubMed Web of Science ®Google Scholar
• Posey J. A., Khazaeli M. B., DelGrosso A., Saleh M. N., Lin C. Y., Huse W., LoBuglio A. F. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm. 2001; 16(2)125–132
   PubMed Web of Science ®Google Scholar
• Eskens F., Dumez H., Verweij J., Perschl A., Kovar A., Brindley C., Van Oosterom A. Phase I and pharmacologic study of EMD 121974, an 3 and 5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors. Presented at: 2000 ASCO Annual Meeting, Abstract 801
   Google Scholar
• Eskens F., Dumez H., Verweij J., et al. Cilengitide (EMD 121974) inhibits angiogenesis by blocking α vβ 3 and α vβ 5 integrins; mature results of a phase I and pharmacological study. Abstract 296. Clin Cancer Res. 2000; 6, (suppl)
   Web of Science ®Google Scholar
• Nabors L. B., Rosenfeld S. S., Mikkelson T., et al. A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Abstract 236. J Neuro-Oncol. 2002; 4(4)
   Google Scholar
• Eskens F. A., Dumez H., Hoekstra R., Perschl A., Brindley C., Bottcher S., Wynendaele W., Drevs J., Verweij J., van Oosterom A. T. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer. 2003; 39(7)917–926
   PubMed Web of Science ®Google Scholar
• Damiano J. S., Cress A. E., Hazlehurst L. A., Shtil A. A., Dalton W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93(5)1658–1667
   PubMed Web of Science ®Google Scholar
• Jensen G. S., Belch A. R., Mant M. J., Ruether B. A., Yacyshyn B. R., Pilarski L. M. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 1993; 43(1)29–36
   PubMed Web of Science ®Google Scholar
• Uchiyama H., Barut B. A., Chauhan D., Cannistra S. A., Anderson K. C. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992; 80(9)2306–2314
   PubMed Web of Science ®Google Scholar
• Uchiyama H., Barut B. A., Mohrbacher A. F., Chauhan D., Anderson K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82(12)3712–3720
   PubMed Web of Science ®Google Scholar
• Gupta D., Treon S. P., Shima Y., Hideshima T., Podar K., Tai Y. T., Lin B., Lentzsch S., Davies F. E., Chauhan D., Schlossman R. L., Richardson P., Ralph P., Wu L., Payvandi F., Muller G., Stirling D. I., Anderson K. C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15(12)1950–1961
   PubMed Web of Science ®Google Scholar
• Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987; 235(4787)442–447
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002; 29: 15–18, (6 Suppl 16)
   PubMed Web of Science ®Google Scholar
• Folkman J. Fundamental concepts of the angiogenic process. Curr Mol. Med. 2003; 3(7)643–651
   PubMed Web of Science ®Google Scholar
• Sledge G. W., Jr., Miller K. D. Angiogenesis and antiangiogenic therapy. Curr Probl. Cancer. 2002; 26(1)1–60
   PubMedGoogle Scholar
• Ellis L. M., Liu W., Ahmad S. A., Fan F., Jung Y. D., Shaheen R. M., Reinmuth N. Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin. Oncol. 2001; 28: 94–104, (5 suppl 16)
   PubMed Web of Science ®Google Scholar
• Cherrington J. M., Strawn L. M., Shawver L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res. 2000; 79: 1–38
   PubMed Web of Science ®Google Scholar
• Gasparini G., Brooks P. C., Biganzoli E., Vermeulen P. B., Bonoldi E., Dirix L. Y., Ranieri G., Miceli R., Cheresh D. A. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998; 4(11)2625–2634
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7)1157–1164
   PubMed Web of Science ®Google Scholar
• Eliceiri B. P., Cheresh D. A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999; 103(9)1227–1230
   PubMed Web of Science ®Google Scholar
• Hynes R. O. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002; 8(9)918–921
   PubMed Web of Science ®Google Scholar
• Hynes R. O., Lively J. C., McCarty J. H., Taverna D., Francis S. E., Hodivala-Dilke K., Xiao Q. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp Quant Biol. 2002; 67: 143–153
   PubMedGoogle Scholar
• Stromblad S., Cheresh D. A. Integrins, angiogenesis and vascular cell survival. Chem Biol. 1996; 3(11)881–885
   PubMed Web of Science ®Google Scholar
• Varner J. A., Cheresh D. A. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol. 1996; 69–87
   PubMedGoogle Scholar
• Varner J. A. The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS 1997; 79: 361–390
   PubMedGoogle Scholar
• Nikolopoulos S. N., Blaikie P., Yoshioka T., Guo W., Giancotti F. G. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell. 2004; 6(5)471–483
   PubMed Web of Science ®Google Scholar
• Tucker G. C. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs. 2003; 4(6)722–731
   PubMedGoogle Scholar
• Eliceiri B. P., Cheresh D. A. Role of alpha v integrins during angiogenesis. Cancer J. 2000; 6: S245–S249, (Suppl 3)
   PubMed Web of Science ®Google Scholar
• Kumar C. C., Armstrong L., Yin Z., Malkowski M., Maxwell E., Ling H., Yaremko B., Liu M., Varner J., Smith E. M., Neustadt B., Nechuta T. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol. 2000; 476: 169–180
   PubMed Web of Science ®Google Scholar
• Scatena M., Giachelli C. The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med. 2002; 12(2)83–88
   PubMed Web of Science ®Google Scholar
• Friedlander M., Theesfeld C. L., Sugita M., Fruttiger M., Thomas M. A., Chang S., Cheresh D. A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 1996; 93(18)9764–9769
   PubMed Web of Science ®Google Scholar
• Marshall J. F., Rutherford D. C., McCartney A. C., Mitjans F., Goodman S. L., Hart I. R. Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin. J Cell Sci. 1995; 108: 1227–1238, (Pt 3)
   PubMed Web of Science ®Google Scholar
• Breuss J. M., Gallo J., DeLisser H. M., Klimanskaya I. V., Folkesson H. G., Pittet J. F., Nishimura S. L., Aldape K., Landers D. V., Carpenter W. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995; 108: 2241–2251, (Pt 6)
   PubMed Web of Science ®Google Scholar
• Thomas G. J., Jones J., Speight P. M. Integrins and oral cancer. Oral Oncol. 1997; 33(6)381–388
   PubMed Web of Science ®Google Scholar
• Sipos B., Hahn D., Carceller A., Piulats J., Hedderich J., Kalthoff H., Goodman S. L., Kosmahl M., Kloppel G. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004; 45(3)226–236
   PubMed Web of Science ®Google Scholar
• Wang T., Li J., Goel H. L., Crockett K., Zhang J., Manes T., FitzGerald T. J., Languino L. R. A novel mechanism of prostate cancer progression mediated by the αvβ integrin. Proc Am Assoc Cancer Res. 2006; 47: LB-324
   Google Scholar
• Munger J. S., Huang X., Kawakatsu H., Griffiths M. J., Dalton S. L., Wu J., Pittet J. F., Kaminski N., Garat C., Matthay M. A., Rifkin D. B., Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3)319–328
   PubMed Web of Science ®Google Scholar
• Thomas G. J., Hart I. R., Speight P. M., Marshall J. F. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer 2002; 87(8)859–867
   PubMed Web of Science ®Google Scholar
• Davidson B., Goldberg I., Reich R., Tell L., Dong H. P., Trope C. G., Risberg B., Kopolovic J. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol. 2003; 90(2)248–257
   PubMed Web of Science ®Google Scholar
• Hibbs K., Skubitz K. M., Pambuccian S. E., Casey R. C., Burleson K. M., Oegema T. R., Jr., Thiele J. J., Grindle S. M., Bliss R. L., Skubitz A. P. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004; 165(2)397–414
   PubMed Web of Science ®Google Scholar
• Kim S., Harris M., Varner J. A. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem. 2000; 275(43)33920–33928
   PubMed Web of Science ®Google Scholar
• Reynolds L. E., Wyder L., Lively J. C., Taverna D., Robinson S. D., Huang X., Sheppard D., Hynes R. O., Hodivala-Dilke K. M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002; 8(1)27–34
   PubMed Web of Science ®Google Scholar
• De S., Razorenova O., McCabe N. P., O'Toole T., Qin J., Byzova T. V. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl. Acad Sci U S A. 2005; 102(21)7589–7594
   PubMed Web of Science ®Google Scholar
• Eliceiri B. P. Integrin and growth factor receptor crosstalk. Circ Res. 2001; 89(12)1104–1110
   PubMed Web of Science ®Google Scholar
• Tucker G. C. Inhibitors of integrins. Curr Opin Pharmacol. 2002; 2(4)394–402
   PubMed Web of Science ®Google Scholar
• Taverna D., Moher H., Crowley D., Borsig L., Varki A., Hynes R. O. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl. Acad Sci U S A. 2004; 101(3)763–768
   PubMed Web of Science ®Google Scholar
• Cheresh D. A., Stupack D. G. Integrin-mediated death: an explanation of the integrin-knockout phenotype?. Nat. Med 2002; 8(3)193–194
   PubMed Web of Science ®Google Scholar
• Hsu M. Y., Shih D. T., Meier F. E., Van Belle P., Hsu J. Y., Elder D. E., Buck C. A., Herlyn M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998; 153(5)1435–1442
   PubMed Web of Science ®Google Scholar
• Kerr J. S., Mousa S. A., Slee A. M. Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 2001; 14(3)143–150
   PubMed Web of Science ®Google Scholar
• Petitclerc E., Stromblad S., von Schalscha T. L., Mitjans F., Piulats J., Montgomery A. M., Cheresh D. A., Brooks P. C. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999; 59(11)2724–2730
   PubMed Web of Science ®Google Scholar
• Mitjans F., Meyer T., Fittschen C., Goodman S., Jonczyk A., Marshall J. F., Reyes G., Piulats J. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000; 87(5)716–723
   PubMed Web of Science ®Google Scholar
• Trikha M., Zhou Z., Nemeth J. A., Chen Q., Sharp C., Emmell E., Giles-Komar J., Nakada M. T. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110(3)326–335
   PubMed Web of Science ®Google Scholar
• Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp. Metastasis 2003; 20(3)203–213
   PubMed Web of Science ®Google Scholar
• Rosano L., Spinella F., Di C. V., Dedhar S., Nicotra M. R., Natali P. G., Bagnato A. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther. 2006; 5(4)833–842
   PubMed Web of Science ®Google Scholar
• Westlin W. F. Integrins as targets of angiogenesis inhibition. Cancer J 2001; 7: S139–S143, (Suppl 3)
   PubMed Web of Science ®Google Scholar
• Leroy-Dudal J., Demeilliers C., Gallet O., Pauthe E., Dutoit S., Agniel R., Gauduchon P., Carreiras F. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer 2005; 114(4)531–543
   PubMed Web of Science ®Google Scholar
• Beck V., Herold H., Benge A., Luber B., Hutzler P., Tschesche H., Kessler H., Schmitt M., Geppert H. G., Reuning U. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int. J Biochem. Cell Biol. 2005; 37(3)590–603
   PubMed Web of Science ®Google Scholar
• Nabors L. B., Fiveash J. Treatment of adults with recurrent malignant glioma. Expert Rev Neurother. 2005; 5(4)509–514
   PubMedGoogle Scholar
• Ding Q., Stewart J., Jr., Prince C. W., Chang P. L., Trikha M., Han X., Grammer J. R., Gladson C. L. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 2002; 62(18)5336–5343
   PubMed Web of Science ®Google Scholar
• Nemeth J. A., Cher M. L., Zhou Z., Mullins C., Bhagat S., Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis. 2003; 20(5)413–420
   PubMed Web of Science ®Google Scholar
• Adams G. P., Schier R., McCall A. M., Simmons H. H., Horak E. M., Alpaugh R. K., Marks J. D., Weiner L. M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61(12)4750–4755
   PubMed Web of Science ®Google Scholar
• Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig. Drugs 2000; 1(2)199–203
   PubMedGoogle Scholar
• Faivre S. J., Chieze S., Marty M., Hammershaimb L., Pluda J., Lozahic S., Armand J. P., Raymond E. Safety profile and pharmacokinetic analysis of medi-522, a novel humanized monoclonal antibody that targets α vβ 3 integrin receptor, in patients with refractory solid tumors. Presented at: 2003 ASCO Annual Meeting, Abstract 832
   Google Scholar
• Pizzolato J. F., Sharma S., Maki R., Krug M., Hammershaimb L., Pluda J. Phase I study of medi-522, an α vβ 3 integrin inhibitor, in patients (pts) with irinotecan-refractory colorectal cancer (CRC). Presented at: 2003 ASCO Annual Meeting, Abstract 983
   Google Scholar
• Wilder R. L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis. 2002; 61: ii96–ii99, (Suppl 2)
   PubMed Web of Science ®Google Scholar
• Hersey P., Sosman J., O'Day S., Richards J., Bedikian A., Gonzalez R., Sharfman W., Weber R., Logan T., Kirkwood J. M. A phase II, randomized, open-label study evaluating the antitumor activity of medi-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). Presented at: 2005 ASCO Annual Meeting, Abstract 7507
   Google Scholar
• Lode H. N., Moehler T., Xiang R., Jonczyk A., Gillies S. D., Cheresh D. A., Reisfeld R. A. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A. 1999; 96(4)1591–1596
   PubMed Web of Science ®Google Scholar
• MacDonald T. J., Taga T., Shimada H., Tabrizi P., Zlokovic B. V., Cheresh D. A., Laug W. E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001; 48(1)151–157
   PubMed Web of Science ®Google Scholar
• Nabors L. B., Rosenfeld S. S., Mikkelsen T., Batchelor T., Olson J., Grossman S., Piantadosi S., Fisher J. D. A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas [Abstract TA-39]. Neuro.-Oncol. 2004; 6(4)379
   Web of Science ®Google Scholar
• Raguse J. D., Gath H. J., Bier J., Riess H., Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 2004; 40(2)228–230
   PubMed Web of Science ®Google Scholar
• Smith J. W. Cilengitide Merck. Curr Opin Investig Drugs. 2003; 4(6)741–745
   PubMedGoogle Scholar
• Chamberlain M. C. Treatment options for glioblastoma. Neurosurg Focus. 2006; 20(4)E2
   Google Scholar
• Jayson G. C., Mullamitha S., Ton C., et al. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to av integrins, in patients with solid tumors. Abstract 382. Ann Oncol. 2004; 15: iii102, (Suppl 3)
   Google Scholar
• Coffey G. P., Stefanich E., Palmieri S., Eckert R., Padilla-Eagar J., Fielder P., Pippig S. In vitro internalization, intracellular transport and clearance of an anti-CD11a antibody (Raptiva™) by human T-cells. J Pharmacol Exp Ther. 2004; 279: 35903–35913
   Google Scholar
• Ricart A., Liu G., Tolcher A., et al. A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors. Eur J Cancer 2004; 2(52), (suppl) (abstract 166)
   Google Scholar
• Funahashi Y., Sugi N. H., Semba T., Yamamoto Y., Hamaoka S., Tsukahara-Tamai N., Ozawa Y., Tsuruoka A., Nara K., Takahashi K., Okabe T., Kamata J., Owa T., Ueda N., Haneda T., Yonaga M., Yoshimatsu K., Wakabayashi T. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002; 62(21)6116–6123
   PubMed Web of Science ®Google Scholar
• Mita M. M., Mita A. C., Goldston M., Chu Q. S., Tolcher A. W., Ricart A., Desai P., Okereke C. S., Rowinsky E. K., Takimoto C. Pharmacokinetics (PK) and pharmcodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: results of a phase I study. Presented at: 2005 ASCO Annual Meeting, Abstract 3082
   Google Scholar
• Simon R., Freidlin B., Rubinstein L., Arbuck S. G., Collins J., Christian M. C. Accelerated titration designs for phase I clinical trials in oncology. J Natl. Cancer Inst. 1997; 89(15)1138–1147
   PubMed Web of Science ®Google Scholar
• Slaton J. W., Perrotte P., Inoue K., Dinney C. P., Fidler I. J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 1999; 5(10)2726–2734
   PubMed Web of Science ®Google Scholar
• Korn E. L., Arbuck S. G., Pluda J. M., Simon R., Kaplan R. S., Christian M. C. Clinical trial designs for cytostatic agents: are new approaches needed?. J Clin Oncol. 2001; 19(1)265–272
   PubMed Web of Science ®Google Scholar
• Eisenhauer E. A. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann. Oncol 1998; 9(10)1047–1052
   PubMed Web of Science ®Google Scholar
• Parulekar W. R., Eisenhauer E. A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl. Cancer Inst. 2004; 96(13)990–997
   PubMed Web of Science ®Google Scholar
• Ellis L. M. Antiangiogenic therapy at a crossroads: clinical trial results and future directions. J Clin Oncol. 2003; 21: 281s–283s, (23 suppl)
   PubMed Web of Science ®Google Scholar
• Fiedler W., Mesters R., Tinnefeld H., Loges S., Staib P., Duhrsen U., Flasshove M., Ottmann O. G., Jung W., Cavalli F., Kuse R., Thomalla J., Serve H., O'Farrell A. M., Jacobs M., Brega N. M., Scigalla P., Hossfeld D. K., Berdel W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003; 102(8)2763–2767
   PubMed Web of Science ®Google Scholar
• McCarty M. F., Liu W., Fan F., Parikh A., Reimuth N., Stoeltzing O., Ellis L. M. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol. Med 2003; 9(2)53–58
   PubMed Web of Science ®Google Scholar
• Morgan B., Thomas A. L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M. A., Mross K., Ball H. A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G. R., Laurent D., Dugan M., Marme D., Steward W. P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003; 21(21)3955–3964
   PubMed Web of Science ®Google Scholar
• Galbraith S. M., Maxwell R. J., Lodge M. A., Tozer G. M., Wilson J., Taylor N. J., Stirling J. J., Sena L., Padhani A. R., Rustin G. J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003; 21(15)2831–2842
   PubMed Web of Science ®Google Scholar
• Hawighorst H., Weikel W., Knapstein P. G., Knopp M. V., Zuna I., Schonberg S. O., Vaupel P., van K. G. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res. 1998; 4(10)2305–2312
   PubMed Web of Science ®Google Scholar
• Pham C. D., Roberts T. P., van B. N., Melnyk O., Mann J., Ferrara N., Cohen R. L., Brasch R. C. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 1998; 16(4)225–230
   PubMed Web of Science ®Google Scholar
• Sipkins D. A., Cheresh D. A., Kazemi M. R., Nevin L. M., Bednarski M. D., Li K. C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998; 4(5)623–626
   PubMed Web of Science ®Google Scholar
• Abramovitch R., Dafni H., Smouha E., Benjamin L. E., Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 1999; 59(19)5012–5016
   PubMed Web of Science ®Google Scholar
• Padhani A. R., Neeman M. Challenges for imaging angiogenesis. Br. J Radiol. 2001; 74(886)886–890
   PubMed Web of Science ®Google Scholar
• Jayson G. C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., Broughton L., Wagstaff J., Hakannson L., Groenewegen G., Bailey J., Smith N., Hastings D., Lawrance J., Haroon H., Ward T., McGown A. T., Tang M., Levitt D., Marreaud S., Lehmann F. F., Herold M., Zwierzina H. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002; 94(19)1484–1493
   PubMed Web of Science ®Google Scholar
• Evelhoch J. L. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999; 10(3)254–259
   PubMed Web of Science ®Google Scholar
• Padhani A. R., Husband J. E. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001; 56(8)607–620
   PubMed Web of Science ®Google Scholar
• Tofts P. S., Brix G., Buckley D. L., Evelhoch J. L., Henderson E., Knopp M. V., Larsson H. B., Lee T. Y., Mayr N. A., Parker G. J., Port R. E., Taylor J., Weisskoff R. M. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson. Imaging 1999; 10(3)223–232
   PubMed Web of Science ®Google Scholar
• Jackson A., Haroon H., Zhu X. P., Li K. L., Thacker N. A., Jayson G. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed. 2002; 15(2)164–173
   PubMed Web of Science ®Google Scholar
• Sotak C. H., Hees P. S., Huang H. N., Hung M. H., Krespan C. G., Raynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med. 1993; 29(2)188–195
   PubMed Web of Science ®Google Scholar
• Zhou J., Payen J. F., Wilson D. A., Traystman R. J., van Zijl P. C. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003; 9(8)1085–1090
   PubMed Web of Science ®Google Scholar
• Robinson S. P., Barton S. J., McSheehy P. M., Griffiths J. R. Nuclear magnetic resonance spectroscopy of cancer. Br J Radiol 1997; 70: S60–S69, (Spec No)
   PubMed Web of Science ®Google Scholar
• Beauregard D. A., Thelwall P. E., Chaplin D. J., Hill S. A., Adams G. E., Brindle K. M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77(11)1761–1767
   PubMed Web of Science ®Google Scholar
• Shukla-Dave A., Zakina K. L., Raizer J., Hricak H., Koutcher J. A. MR spectroscopy of tumor physiology. Principles and Practice of Oncology:Updates. Lippincott Williams & Wilkins, Philadelphia 2003
   Google Scholar
• Gupta N., Price P. M., Aboagye E. O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 2002; 38(16)2094–2107
   PubMed Web of Science ®Google Scholar
• Nakamoto Y., Zasadny K. R., Minn H., Wahl R. L. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol. 2002; 4(2)171–178
   PubMedGoogle Scholar
• Flamen P., Lerut T., Haustermans K., Van C. E., Mortelmans L. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q. J Nucl Med Mol. Imaging 2004; 48(2)96–108
   PubMed Web of Science ®Google Scholar
• Smith T. A. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun. 1998; 19(2)97–105
   PubMed Web of Science ®Google Scholar
• Koh W. J., Rasey J. S., Evans M. L., Grierson J. R., Lewellen T. K., Graham M. M., Krohn K. A., Griffin T. W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22(1)199–212
   PubMed Web of Science ®Google Scholar
• Wells P., Harte R. J., Price P. Positron emission tomography: a new investigational area for cancer research. Clin Oncol (R Coll. Radiol). 1996; 8(1)7–14
   PubMedGoogle Scholar
• Bakir M. A., Eccles S., Babich J. W., Aftab N., Styles J., Dean C. J., Lambrecht R. M., Ott R. J. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med. 1992; 33(12)2154–2160
   PubMed Web of Science ®Google Scholar
• Collingridge D. R., Carroll V. A., Glaser M., Aboagye E. O., Osman S., Hutchinson O. C., Barthel H., Luthra S. K., Brady F., Bicknell R., Price P., Harris A. L. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002; 62(20)5912–5919
   PubMed Web of Science ®Google Scholar
• Dehdashti F., Mortimer J. E., Siegel B. A., Griffeth L. K., Bonasera T. J., Fusselman M. J., Detert D. D., Cutler P. D., Katzenellenbogen J. A., Welch M. J. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl. Med. 1995; 36(10)1766–1774
   PubMed Web of Science ®Google Scholar
• Chen X., Park R., Shahinian A. H., Tohme M., Khankaldyyan V., Bozorgzadeh M. H., Bading J. R., Moats R., Laug W. E., Conti P. S. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004; 31(2)179–189
   PubMed Web of Science ®Google Scholar
• Beer A. J., Haubner R., Wolf I., Goebel M., Luderschmidt S., Niemeyer M., Grosu A. L., Martinez M. J., Wester H. J., Weber W. A., Schwaiger M. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006; 47(5)763–769
   PubMed Web of Science ®Google Scholar
• Haubner R., Weber W. A., Beer A. J., Vabuliene E., Reim D., Sarbia M., Becker K. F., Goebel M., Hein R., Wester H. J., Kessler H., Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS. Med. 2005; 2(3)e70.
   PubMed Web of Science ®Google Scholar
• Beer A. J., Haubner R., Goebel M., Luderschmidt S., Spilker M. E., Wester H. J., Weber W. A., Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl. Med. 2005; 46(8)1333–1341
   PubMed Web of Science ®Google Scholar
• Cai W., Gambhir S., Chen X. Multimodality tumor imaging targeting integrin avβ3. Biotechniques 2005; 39: S6–S17, (Supplement)
   PubMedGoogle Scholar
• Glaser M., Collingridge D. R., Aboagye E. O., Bouchier-Hayes L., Hutchinson O. C., Martin S. J., Price P., Brady F., Luthra S. K. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot. 2003; 58(1)55–62
   PubMed Web of Science ®Google Scholar
• Jain R. K., Duda D. G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell. 2003; 3(6)515–516
   PubMed Web of Science ®Google Scholar
• Rohan R. M., Fernandez A., Udagawa T., Yuan J., D'Amato R. J. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000; 14(7)871–876
   PubMed Web of Science ®Google Scholar
• Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001; 97(11)3658–3661
   PubMed Web of Science ®Google Scholar
• Willett C. G., Boucher Y., di T. E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2)145–147
   PubMed Web of Science ®Google Scholar
• Shaked Y., Bertolini F., Man S., Rogers M. S., Cervi D., Foutz T., Rawn K., Voskas D., Dumont D. J., Ben-David Y., Lawler J., Henkin J., Huber J., Hicklin D. J., D'Amato R. J., Kerbel R. S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005; 7(1)101–111
   PubMed Web of Science ®Google Scholar
• Lockhart A. C., Braun R. D., Yu D., Ross J. R., Dewhirst M. W., Klitzman B., Yuan F., Grichnik J. M., Proia A. D., Conway D. A., Mann G., Hurwitz H. I. A clinical model of dermal wound angiogenesis. Wound Repair Regen. 2003; 11(4)306–313
   PubMed Web of Science ®Google Scholar
• Lockhart A. C., Braun R. D., Yu D., Ross J. R., Dewhirst M. W., Humphrey J. S., Thompson S., Williams K. M., Klitzman B., Yuan F., Grichnik J. M., Proia A. D., Conway D. A., Hurwitz H. I. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res. 2003; 9(2)586–593
   PubMed Web of Science ®Google Scholar
• Fehm T., Sagalowsky A., Clifford E., Beitsch P., Saboorian H., Euhus D., Meng S., Morrison L., Tucker T., Lane N., Ghadimi B. M., Heselmeyer-Haddad K., Ried T., Rao C., Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002; 8(7)2073–2084
   PubMed Web of Science ®Google Scholar
• Cristofanilli M., Budd G. T., Ellis M. J., Stopeck A., Matera J., Miller M. C., Reuben J. M., Doyle G. V., Allard W. J., Terstappen L. W., Hayes D. F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8)781–791
   PubMed Web of Science ®Google Scholar
• Larson C. J., Moreno J. G., Pienta K. J., Gross S., Repollet M., O'hara S. M., Russell T., Terstappen L. W. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62(1)46–53
   PubMedGoogle Scholar
• Cohen S. J., Alpaugh R. K., Allard J., Cheng J. D., Gross S. T., Lewis N. L., Rogatko A., Sigurdson E., Weiner L. M., Meropol N. J. Isolation and characterization of circulating tumor cells in patients with colorectal cancer. Presented at: ASCO Annual Meeting 2003. Abstract 1186. Proc Am Soc Clin Oncol. 22: 295
   Google Scholar
• Horton M. A., Taylor M. L., Arnett T. R., Helfrich M. H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res. 1991; 195(2)368–375
   PubMed Web of Science ®Google Scholar
• Ross F. P., Chappel J., Alvarez J. I., Sander D., Butler W. T., Farach-Carson M. C., Mintz K. A., Robey P. G., Teitelbaum S. L., Cheresh D. A. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993; 268(13)9901–9907
   PubMed Web of Science ®Google Scholar
• Inoue M., Teitelbaum S. L., Hurter L., Hruska K., Seftor E., Hendrix M., Ross F. P. GM-CSF regulates expression of the functional integrins v3 and v5 in a reciprocal manner during osteoclastogenesis. J Bone Miner Res. 1995; 10: S163a
   Google Scholar
• Delmas P. D., Eastell R., Garnero P., Seibel M. J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000; 11: S2-17, (Suppl 6)
   PubMedGoogle Scholar
• Stadler W. M., Ratain M. J. Development of target-based antineoplastic agents. Invest New Drugs. 2000; 18(1)7–16
   PubMed Web of Science ®Google Scholar
• Liu S. Y., Eary J. F., Petersdorf S. H., Martin P. J., Maloney D. G., Appelbaum F. R., Matthews D. C., Bush S. A., Durack L. D., Fisher D. R., Gooley T. A., Bernstein I. D., Press O. W. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998; 16(10)3270–3278
   PubMed Web of Science ®Google Scholar
• Zee B., Melnychuk D., Dancey J., Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat. 1999; 9(2)351–363
   PubMedGoogle Scholar
• Casper E. S., Green M. R., Kelsen D. P., Heelan R. T., Brown T. D., Flombaum C. D., Trochanowski B., Tarassoff P. G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994; 12(1)29–34
   PubMed Web of Science ®Google Scholar
• Burris H. A., III, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelson R., Dorr F. A., Stephens C. D., Von Hoff D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6)2403–2413
   PubMed Web of Science ®Google Scholar
• Simon R., Wittes R. E., Ellenberg S. S. Randomized phase II clinical trials. Cancer Treat Rep. 1985; 69(12)1375–1381
   PubMedGoogle Scholar
• Leyland-Jones B. Maximizing the response to Herceptin therapy through optimal use and patient selection. Anticancer Drugs. 2001; 12: S11–S17, (Suppl 4)
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 2002; 3(3)137–144
   PubMed Web of Science ®Google Scholar
• Bilous M., Dowsett M., Hanna W., Isola J., Lebeau A., Moreno A., Penault-Llorca F., Ruschoff J., Tomasic G., van D. Current V. perspectives on HER2 testing: a review of national testing guidelines. Mod. Pathol. 2003; 16(2)173–182
   PubMed Web of Science ®Google Scholar
• Yamauchi H., Stearns V., Hayes D. F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19(8)2334–2356
   PubMed Web of Science ®Google Scholar
• Hanna W. M., Kahn H. J., Pienkowska M., Blondal J., Seth A., Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol. 2001; 14(7)677–685
   PubMed Web of Science ®Google Scholar
• Tsongalis G. J., Ried A. Jr. HER2: the neu prognostic marker for breast cancer. Crit Rev Clin Lab Sci. 2001; 38(2)167–182
   PubMed Web of Science ®Google Scholar
• Sledge G. W., Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol. 2002; 29: 104–110, (3 Suppl 11)
   PubMed Web of Science ®Google Scholar
• Kuenen B. C., Tabernero J., Baselga J., Cavalli F., Pfanner E., Conte P. F., Seeber S., Madhusudan S., Deplanque G., Huisman H., Scigalla P., Hoekman K., Harris A. L. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003; 9(5)1648–1655
   PubMed Web of Science ®Google Scholar
• Trikha M., Zhou Z., Nemeth J. A., Chen Q., Sharp C., Emmell E., Giles-Komar J., Nakada M. T. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110(3)326–335
   PubMed Web of Science ®Google Scholar
• Chen H. X. Expanding the clinical development of bevacizumab. Oncologist 2004; 9: 27–35, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Gerber H. P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005; 65(3)671–680
   PubMed Web of Science ®Google Scholar
• Chen H. X., Gore-Langton R. E., Cheson B. D. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 2001; 15(8)1017, 1020, 1023, 1026
   PubMed Web of Science ®Google Scholar
• Margolin K., Gordon M. S., Holmgren E., Gaudreault J., Novotny W., Fyfe G., Adelman D., Stalter S., Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001; 19(3)851–856
   PubMed Web of Science ®Google Scholar
• Wildiers H., Guetens G., De B. G., Verbeken E., Landuyt B., Landuyt W., de Bruijn E. A., van Oosterom A. T. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88(12)1979–1986
   PubMed Web of Science ®Google Scholar
• Genentech I. Avastin™ (bevacizumab). US prescribing information. 2005. South San Francisco, CA 2005
   Google Scholar
• DeNardo S. J., Burke P. A., Leigh B. R., O'Donnell R. T., Miers L. A., Kroger L. A., Goodman S. L., Matzku S., Jonczyk A., Lamborn K. R., DeNardo G. L. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm 2000; 15(1)71–79
   PubMed Web of Science ®Google Scholar
• Burke P. A., DeNardo S. J., Miers L. A., Lamborn K. R., Matzku S., DeNardo G. L. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002; 62(15)4263–4272
   PubMed Web of Science ®Google Scholar
• Li L., Wartchow C. A., Danthi S. N., Shen Z., Dechene N., Pease J., Choi H. S., Doede T., Chu P., Ning S., Lee D. Y., Bednarski M. D., Knox S. J. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004; 58(4)1215–1227
   PubMed Web of Science ®Google Scholar
• Fahr A., Muller K., Nahde T., Muller R., Brusselbach S. A new colloidal lipidic system for gene therapy. J Liposome Res. 2002; 12(1-2)37–44
   PubMed Web of Science ®Google Scholar
• Reynolds A. R., Moein M. S., Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumour neovasculature. Trends Mol Med. 2003; 9(1)2–4
   PubMed Web of Science ®Google Scholar
• McQuade P., Knight L. C. Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med. 2003; 47(3)209–220
   PubMedGoogle Scholar